 |
|
 |
Drug Discovery |
|
|
Emerging Drug Discovery Technologies
Building competitive advantage through lab-on-a-chip, nanotechnology and RNAi
Publication Date January 2005
Publisher Business Insights
Product Type Report
Pages 186
ISBN Number 1-84296-193-4
Product Code RBI044
|
|
|
Summary
The last decade has been marked by an unprecedented boom in the number and variety of technologies used to discover and develop new drugs; many of these technologies arose from work surrounding the human genome project. For example, gene sequencing, gene expression profiling and genotyping have greatly benefited from technological advances, resulting in dramatically higher throughputs and rapid declines in cost. For some other areas it has proven to be more of a challenge to achieve performance improvements of the same magnitude. Defining the function of each gene, or more specifically, the protein it encodes, has been particularly challenging. It is not yet possible to study gene function with the type of "massively parallel" approaches used in other fields.
|
Content
- Executive Summary
- Introduction
- Lab-On-A-Chip/Microfluidics
- Nanotechnology
- Rna Interference
- Chapter 1 Introduction
- Summary
- Overview
- A Historical Overview Of The Drug Discovery Process
- Drug Discovery In The 1950s And 1960s
- Drug Discovery In The 1980s
- Drug Discovery Today
- Emerging Drug Discovery Technologies
- Lab-On-A-Chip/Microfluidic Technologies
- Nanotechnology
- Rna Interference
- Report Objectives
- Chapter 2 Lab-On-A-Chip/Microfluidics
- Summary
- Introduction
- Loc Technologies
- Loc Design Issues
- Microarrays
- Spotted Microarrays
- In Situ Fabricated Arrays
- Dna Applications
- Protein Applications
- The Labchip
- Lab-On-A-Cd
- Chip-Based Electrospray System For Mass Spectroscopy
- Hplc-On-A-Chip
- Microfluidic Pcr
- Multiplexed Capillary Electrophoresis
- Market Drivers And Restraints
- Market Drivers
- Hts
- Reduction Of Human Error
- Reduced Exposure To Hazardous Materials
- Reduction In Sample Requirement And Routine Tasks
- Cost Savings
- Market Restraints
- Reduction In Demand
- Reluctance To Replace Old Systems With New Technologies
- Market Analysis
- Competitive Structure
- Market Share
- Aclara Biosciences
- Advion Biosciences, Inc.
- Agilent Technologies
- Biomicro Systems
- Biotrove Inc.
- Caliper Life Sciences
- Cepheid
- Combimatrix Corp.
- Eksigent Technologies
- Epigem Limited
- Fluidigm Corp.
- Gyros Ab
- Nanogen
- Nanostream Inc.
- Protiveris
- Sequenom
- Zyomyx
- Future Developments
- Chapter 3 Nanotechnology
- Summary
- Introduction
- Nanotechnologies
- Applications
- Drug Discovery And Drug Delivery
- Biosensing
- Other Applications
- Public Opinion
- Funding
- Market
- Nano-Enabled Drug Discovery Tools
- Atomic Force Microscopy
- Nano-Mass Spectroscopy
- Dip-Pen Nanolithography
- Nanoarrays
- Nanoparticles For Drug Discovery
- Quantum Dots And Gold Nanoparticles
- Nanoshells
- Nanobarcode Particles
- Nano-Enabled Drugs
- Abraxane
- Renazorb
- Antimicrobial Emulsions
- Antioxidants And Fullerenes
- Industry Challenges
- High Demands Of Drug Discovery Applications
- Long-Term Stability Of Nanomaterials
- Technical Issues In Nano-Assembly And Molecular Manufacturing
- Barriers To Collaborations
- Lack Of Test Standardization
- Scalability
- Pharmaceutical Companies Reluctant To Invest In Nanotechnology
- Funding For Nanotechnology
- Market Drivers And Restraints
- Market Drivers
- Technological Drivers
- Increased Funding
- Social And Economic Factors
- Market Restraints
- Uncertainty
- Public Awareness
- Environmental Concerns
- Detection Of Incurable Diseases
- Large Expectations
- Market Analysis
- Competitive Structure
- Market Share
- 3dm Inc.
- Alnis Biosciences Inc.
- American Pharmaceuticals Partners Inc.
- Biocrystal Ltd.
- Bioforce Nanosciences Inc.
- Crystalplex Corp.
- C Sixty Inc.
- Evident Technologies, Inc.
- Nanbio Corp.
- Nanosphere
- Pharmaseq, Inc
- Quantum Dot Corp.
- Future Developments
- Chapter 4 Rna Interference (Rnai)
- Summary
- Introduction
- Gene Silencing
- Methods For Gene Silencing
- Aptamers
- Ribozymes
- Peptide Nucleic Acid (Pna) And Pna-Dna Chimeras
- Antisense Oligonucleotides
- Rna Interference (Rnai)
- Rnai Mechanism
- Rnai Approaches
- Sirna
- Ddrnai
- Micrornas (Mirnas)
- Short Hairpin Rnas (Shrnas)
- Delivery Methods
- Delivery Using Chemical Transfections
- Delivery Using Electroporation
- Delivery Using Expression Vectors
- Delivery Using Cell-Penetrating Peptides
- In Vivo Delivery Of Sirnas
- Industry Challenges
- Intellectual Property Issues
- Off-Target Effects
- Delivery Of Sirna In Vitro And In Vivo
- Toxicity Issues From Rnai
- Pricing Issues
- Efficacy Of Rnai
- Standardization Of Technologies
- Proof Of Therapeutic Potential
- Market Drivers And Restraints
- Market Drivers
- Demand For Accelerated Drug Discovery
- Resolution Of Intellectual Property Issues
- Robust, Efficient And Potent Technology
- Functional Genomics And Proteomics Studies
- Vector-Based And Sirna Price Decline
- Reliability
- Market Restraints
- Expensive Rnai Reagents
- Delivery Of Sirna
- Failure Of Antisense Drugs
- Lack Of Robust Clinical Data
- Selection And Design Of Appropriate Sirna
- Toxicity And Off-Target Effects
- Market Analysis
- Revenue Forecasts
- Trends By Geographic Region
- North America
- Europe
- Japan
- Rest Of The World
- Competitive Structure
- Market Share Analysis
- Ambion
- Alnylam Pharmaceuticals, Inc.
- Benitec Ltd
- Cytrx Corp.
- Cenix Bioscience
- Devgen
- Dharmacon, Inc.
- Eurogentec (Egt)
- Imgenex Corp.
- Immusol Inc.
- Invitrogen Corp.
- Invivogen
- Mwg Biotech
- Proligo
- Promega
- Qiagen.
- Sirna Therapeutics
- Future Developments
- Chapter 5 Appendix
- Research Methodology And Information Sources
- Primary Research Methodology
- Secondary Research Methodology
- Market Sizing
- Forecasting
- Index
- Abbreviations And Acronyms
- List Of Figures
- Figure 1.1: Drug Development Process During The 1950s And 1960s
- Figure 1.2: Drug Development Process During The 1980s
- Figure 1.3: Drug Development Process Today
- Figure 2.1: The Gyros Bioaffy Lab-On-A-Cd
- Figure 2.2: Advion Biosciences' Esi Chip
- Figure 2.3: Hplc-On-A-Chip
- Figure 2.4: Cepheid's Genexpert Cartridges For Pcr Analysis
- Figure 2.5: Market Drivers And Restraints For Loc/Microfluidics Devices In Drug Discovery
- Figure 2.6: Microfluidics/Loc Revenue Forecasts, 2005-2012
- Figure 2.7: Microfluidics/Lab-On-A-Chip Market Shares, 2004
- Figure 3.1: Expression Of Cells Using Qdots
- Figure 3.2: Binding Of Nanosphere's Nanoparticle Probe To A Selected Genetic Or Proteomic Target
- Figure 3.3: Nano-Enabled Drug Discovery Industry Challenges
- Figure 3.4: Market Drivers And Restraints For Nano-Enabled Drug Discovery
- Figure 3.5: Nano-Enabled Drug Discovery Revenue Forecasts, 2004-2012
- Figure 3.6: Nanoenabled Drug Discovery Market Shares, 2004
- Figure 4.7: Rnai Pathways
- Figure 4.8: Industry Challenges Faced By Rnai Industry Participants
- Figure 4.9: Market Drivers And Restraints For Rnai Technology
- Figure 4.10: Rnai Revenue Forecasts And Growth Rates, 2004-2012
- Figure 4.11: Rnai Revenues By Geographic Region, 2004
- Figure 4.12 Rnai Market Shares, 2004
- List Of Tables
- Table 2.1: Microfluidics/Loc Revenue Forecasts, 2005-2012
- Table 3.2: Nano-Enabled Drug Discovery Revenue Forecasts, 2004-2012
- Table 4.3: Rnai Revenue Forecasts, 2004-2012
- Table 5.4: Abbreviations And Acronyms, A-L
- Table 5.5: Abbreviations And Acronyms, M-Z 186
|
|
|
